Compare Analog Devices, Inc. (ADI) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs Adaptive Biotechnologies Corp — how do they compare? Analog Devices, Inc. trades at $384.44 (market cap $187.67B), while Adaptive Biotechnologies Corp trades at $24.94 (market cap $4.04B). The key difference: Analog Devices, Inc. is far larger — about 46.5× Adaptive Biotechnologies Corp's market cap, and Analog Devices, Inc. pays a 1.14% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADI | ADPT | |
|---|---|---|
Market Cap | $187.67B | $4.04B |
Sector | Technology | Health |
52-Week High | $445.48 | $25.45 |
52-Week Low | $225.20 | $12.30 |
Enterprise Value | $192.92B | $4.10B |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $384.29, up 0.1% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q1 2026 EPS of $3.09, exceeding expectations, and maintains strong profitability with a 26.01% net income margin. A dividend of $1.10 per share is scheduled for payment on June 16, 2026, reflecting cash flow stability.
ADI presents a favorable investment case with analyst consensus strongly bullish (79.63% buy ratings) and a price target of $472.29, implying significant upside. Risks include elevated valuation multiples (P/E of 57.34) and semiconductor cycle volatility, but robust fundamentals and AI-driven demand support long-term growth prospects.
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →
